Negin Rahmani
With over 15 years of pharmaceutical industry expertise, Negin Rahmani is well-versed in all stages of drug development and medical affairs. Prior to founding Complete Phase, Negin worked at a leading phase 1 clinical trial unit in Australia where she gained hands-on experience in site-level clinical trial management.
She later transitioned to roles at leading CROs and pharmaceutical companies, providing her with a comprehensive understanding of the end-to-end processes involved in bringing pharmaceutical products to market.
Equipped with a bachelor's degree in pharmaceutical science and an MBA from Melbourne Business School, Negin combines technical proficiency with business acumen to deliver top-notch services to clients.
Howard Wraight
Dr. Howard Wraight is a is a highly experienced professional with over 40 years of experience in pharmaceuticals and clinical research. Based in Australia, he is a registered Medical Doctor, Medical Monitor, and Clinician, specializing in HIV and viral hepatitis healthcare.
Dr. Wraight has held key leadership roles at Novotech, Gilead Sciences, and SmithKline Beecham, where he established medical departments, drove clinical research investments, and secured PBS listings for various drugs.
His educational background includes a MB BS from the University of Melbourne and a Diploma in Theology from Capernwray College in the UK. Dr. Wraight's diverse expertise across all phases of clinical research and a wide range of therapeutic areas underscore his dedication to advancing medical research and clinical practice.
Dirk Hoenemann
Dr. Hoenemann, a registered clinician, has extensive expertise in Medical leadership, including Medical Affairs, Clinical Development, and Pharmacovigilance. Specializing in hematology, Dr. Hoenemann has shaped practices in Myeloma, Myelodysplasia, andPancreatic Cancer through regular interactions with government bodies, including TGA, FDA and department of Health. He also pioneered Phase I trials, initiating Australia's first CAR-T study and establishing an immunological translational research lab.
Moreover, Dr. Hoenemann possesses extensive insights into the Asia-Pacific market, acquired through regional leadership roles and actively contributing to global strategic initiatives.
Dr. Hoenemann's expertise in immunotherapy, cellular therapy, and drug development principles fosters innovation and collaboration across sectors, driving advancements in global health initiatives.
Kaylene O'shea
Kaylene O'Shea is a highly experienced leader with a proven track record across global pharmaceuticals, healthcare, and not-for-profit sectors. With extensive experience at CSL, Amgen, Celgene, and Bristol Myers-Squibb, she brings a wealth of expertise in leading teams and multinational projects.
Kaylene's leadership roles span the functions of Clinical Operations, Scientific Affairs, and Corporate Affairs. Over her career, Kaylene has been instrumental in driving successful product launches and spearheading strategic planning initiatives.
With a Master of Management from Monash University and a Bachelor of Applied Science from the Sydney Institute of Technology, Kaylene has a solid academic foundation that underpins her extensive practical experience.
Anthony Treacy
Anthony is a Clinical research and development professional with over twenty years of industry experience spanning multiple therapy areas across pre-clinical to post-marketing phases in Biotech, Pharma, and CRO companies.
Throughout his career, he has adeptly managed clinical research & development operations, and facilitated strategic collaborations in hematology/oncology & other therapeutic areas. He excels in managing programs, evaluating vendors, and fostering crucial relationships in Biotech, Pharma, and CRO sectors.
Anthony's diverse experience, combined with his track record of driving success in clinical research programs, positions him as a valuable asset to any organization in the pharmaceutical and biotech industries.
Tracina Williams
Tracina brings over 15 years of experience across Phase I–IV clinical trials, with deep expertise in early-phase execution, study start-up, and regulatory delivery in Australia and New Zealand.
She has
held senior roles at Pfizer, Parexel, and TFS CRO, leading clinical operations, regulatory submissions, and site activation across complex global trials. Throughout her career, she has worked across a broad range of therapeutic areas, partnering with sponsors, investigators, ethics committees, and regulatory bodies to navigate study start-up and operational challenges. Her experience spans both sponsor and CRO environments, providing a practical understanding of the priorities, timelines, and quality expectations required to successfully deliver clinical programs.
Tracina combines hands-on delivery with strategic oversight, ensuring studies are executed efficiently, compliantly, and without unnecessary delays. She is known for her proactive approach to problem-solving, strong stakeholder management, and ability to drive cross-functional collaboration. From feasibility and site selection through to activation and ongoing trial management, she focuses on creating streamlined processes that accelerate study timelines while maintaining the highest standards of quality and regulatory compliance.
Negin Rahmani
With over 15 years of pharmaceutical industry expertise, Negin Rahmani is well-versed in all stages of drug development and medical affairs. Prior to founding Complete Phase, Negin worked at a leading phase 1 clinical trial unit in Australia where she gained hands-on experience in site-level clinical trial management.
She later transitioned to roles at leading CROs and pharmaceutical companies, providing her with a comprehensive understanding of the end-to-end processes involved in bringing pharmaceutical products to market.
Equipped with a bachelor's degree in pharmaceutical science and an MBA from Melbourne Business School, Negin combines technical proficiency with business acumen to deliver top-notch services to clients.
Kaylene O'shea
Kaylene O'Shea is a highly experienced leader with a proven track record across global pharmaceuticals, healthcare, and not-for-profit sectors. With extensive experience at CSL, Amgen, Celgene, and Bristol Myers-Squibb, she brings a wealth of expertise in leading teams and multinational projects.
Kaylene's leadership roles span the functions of Clinical Operations, Scientific Affairs, and Corporate Affairs. Over her career, Kaylene has been instrumental in driving successful product launches and spearheading strategic planning initiatives.
With a Master of Management from Monash University and a Bachelor of Applied Science from the Sydney Institute of Technology, Kaylene has a solid academic foundation that underpins her extensive practical experience.
Howard Wraight
Dr. Howard Wraight is a is a highly experienced professional with over 40 years of experience in pharmaceuticals and clinical research. Based in Australia, he is a registered Medical Doctor, Medical Monitor, and Clinician, specializing in HIV and viral hepatitis healthcare.
Dr. Wraight has held key leadership roles at Novotech, Gilead Sciences, and SmithKline Beecham, where he established medical departments, drove clinical research investments, and secured PBS listings for various drugs.
His educational background includes a MB BS from the University of Melbourne and a Diploma in Theology from Capernwray College in the UK. Dr. Wraight's diverse expertise across all phases of clinical research and a wide range of therapeutic areas underscore his dedication to advancing medical research and clinical practice.
Anthony Treacy
Anthony is a Clinical research and development professional with over twenty years of industry experience spanning multiple therapy areas across pre-clinical to post-marketing phases in Biotech, Pharma, and CRO companies.
Throughout his career, he has adeptly managed clinical research & development operations, and facilitated strategic collaborations in hematology/oncology & other therapeutic areas. He excels in managing programs, evaluating vendors, and fostering crucial relationships in Biotech, Pharma, and CRO sectors.
Anthony's diverse experience, combined with his track record of driving success in clinical research programs, positions him as a valuable asset to any organization in the pharmaceutical and biotech industries.
Dirk Hoenemann
Dr. Hoenemann, a registered clinician, has extensive expertise in Medical leadership, including Medical Affairs, Clinical Development, and Pharmacovigilance. Specializing in hematology, Dr. Hoenemann has shaped practices in Myeloma, Myelodysplasia, andPancreatic Cancer through regular interactions with government bodies, including TGA, FDA and department of Health. He also pioneered Phase I trials, initiating Australia's first CAR-T study and establishing an immunological translational research lab.
Moreover, Dr. Hoenemann possesses extensive insights into the Asia-Pacific market, acquired through regional leadership roles and actively contributing to global strategic initiatives.
Dr. Hoenemann's expertise in immunotherapy, cellular therapy, and drug development principles fosters innovation and collaboration across sectors, driving advancements in global health initiatives.
Tracina Williams
Tracina brings over 15 years of experience across Phase I–IV clinical trials, with deep expertise in early-phase execution, study start-up, and regulatory delivery in Australia and New Zealand.
She has
held senior roles at Pfizer, Parexel, and TFS CRO, leading clinical operations, regulatory submissions, and site activation across complex global trials. Throughout her career, she has worked across a broad range of therapeutic areas, partnering with sponsors, investigators, ethics committees, and regulatory bodies to navigate study start-up and operational challenges. Her experience spans both sponsor and CRO environments, providing a practical understanding of the priorities, timelines, and quality expectations required to successfully deliver clinical programs.
Tracina combines hands-on delivery with strategic oversight, ensuring studies are executed efficiently, compliantly, and without unnecessary delays. She is known for her proactive approach to problem-solving, strong stakeholder management, and ability to drive cross-functional collaboration. From feasibility and site selection through to activation and ongoing trial management, she focuses on creating streamlined processes that accelerate study timelines while maintaining the highest standards of quality and regulatory compliance.
